__timestamp | Amphastar Pharmaceuticals, Inc. | Galapagos NV |
---|---|---|
Wednesday, January 1, 2014 | 40373000 | 9079000 |
Thursday, January 1, 2015 | 46974000 | 20309000 |
Friday, January 1, 2016 | 47298000 | 16945000 |
Sunday, January 1, 2017 | 50918000 | 20559000 |
Monday, January 1, 2018 | 58044000 | 29641000 |
Tuesday, January 1, 2019 | 63109000 | 88258000 |
Wednesday, January 1, 2020 | 65157000 | 162170000 |
Friday, January 1, 2021 | 68920000 | 167218000 |
Saturday, January 1, 2022 | 66592000 | 239528000 |
Sunday, January 1, 2023 | 80393000 | 94252000 |
Infusing magic into the data realm
In the ever-evolving landscape of biopharmaceuticals, cost management remains a pivotal factor for success. Amphastar Pharmaceuticals, Inc. and Galapagos NV, two prominent players, have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Amphastar's SG&A expenses grew steadily, peaking at approximately 80 million USD in 2023, marking a 99% increase from 2014. In contrast, Galapagos NV experienced a more volatile trajectory, with expenses surging by over 2500% from 2014 to 2022, before a notable decline in 2023. This divergence highlights the strategic differences in cost management and operational scaling between the two companies. As the industry continues to innovate, understanding these financial dynamics offers valuable insights into the strategic priorities and market positioning of these biopharma leaders.
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Galapagos NV Trends and Insights
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Bio-Techne Corporation vs Galapagos NV: SG&A Expense Trends
Walgreens Boots Alliance, Inc. or Galapagos NV: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Galapagos NV
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Galapagos NV
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Merus N.V. or Galapagos NV
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Galapagos NV Trends and Insights
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.